Domain Therapeutics is a preclinical-stage biopharmaceutical company dedicated to the discovery and development of innovative treatments for immuno-oncology. With teams at work in France and Canada, Domain operates multiple technologies aimed at validating G Protein-Coupled Receptors (GPCRs) mediating immunosuppression, at discovering first-in-class or best-in-class therapies, small molecules and antibodies, and at developing them in the clinic to create a pipeline of high-value proprietary programs.